INOVIO Announces Appointment of Steven Egge as Chief Commercial Officer

Mr. Egge brings more than 25 years of biopharmaceutical experience building commercial organizations and successfully launching new therapeutic products.

INOVIO is on track to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in the second half of 2024 under the U.S. Food and Drug Administration’s accelerated approval pathway

PLYMOUTH MEETING, PA, July 2, 2024 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA-based medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced the appointment of Steven Egge as Chief Commercial Officer. Mr. Egge will lead the Company’s commercial strategy and operations as it prepares to potentially launch its first DNA-based medical product, INO-3107 as a treatment for recurrent respiratory papillomatosis (RRP).

“We are delighted to welcome Steve to INOVIO and look forward to adding his expertise to our leadership team as we continue to advance our preparations for the commercial launch of INO-3107 in 2025, if it receives FDA approval as a treatment for RRP,” said Dr. Jacqueline SheaPresident and CEO of INOVIO. “Steve joins us at an exciting time as we prepare to become a commercial-stage company while advancing multiple product candidates targeting unmet medical needs. His expertise in launching new products, growing market share in competitive environments and driving overall therapeutic area growth will be beneficial to the development and execution of our commercial plans, as will his experience in immunology and vaccines, HPV and rare diseases.”

“This is an ideal time to join INOVIO as the company has the opportunity to commercialize the first treatment option for patients suffering from RRP, a rare and debilitating HPV-related disease that significantly impacts quality of life,” said Mr. Egge. “I look forward to working with INOVIO’s talented team and continuing the ongoing efforts to expand the company’s commercial strategies and capabilities.”

Mr. Egge joins INOVIO from Sumitomo Pharma (formerly Myovant Sciences, acquired by Sumitovant Biopharma, a subsidiary of Sumitomo Pharma, in 2023), where he was Senior Vice President and General Manager of Women’s Health, responsible for building the commercial leadership team, accelerating the launch of Myfembree® and helping lead the company’s expansion into new indications. Mr. Egge joined Merck for twenty years, where he held several senior commercial leadership roles, including leading Merck’s HPV vaccine franchise and serving as Chief Marketing Officer of the Vaccines Division, where he oversaw the launches of new indications for GARDASIL®, the relaunch of ZOSTAVAX® and the launch planning for GARDASIL9® and VAXELIS®. Mr. Egge also served as Global Commercial Director for Merck’s Fertility franchise, where he oversaw the launch of ELONVA® in markets outside the United States. Following Merck, Mr. Egge served as Senior Vice President at Genfit Corp., a French biotechnology company focused on liver diseases, where he led commercial planning and business development.

About INOVIO’s DNA Medicines Platform
INOVIO’s DNA medicines platform features two innovative elements: precisely designed DNA plasmids delivered by INOVIO’s proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small, circular DNA molecules that function like software that cells in the body can download to produce specific proteins to target and fight disease. INOVIO’s proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to cells in the body without the need for chemical adjuvants or lipid nanoparticles and without the risk of anti-vector responses historically seen with viral vector platforms.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA-based medicines to treat and protect people from HPV-related diseases, cancer and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to make its own disease-fighting tools. For more information, visit www.inovio.com.

CELLECTRA® is a registered trademark of INOVIO.
GARDASIL®GARDASIL9®ZOSTAVAX® and ELONVA® are registered trademarks of Merck and Co., Inc.
VAXELIS® is a registered trademark of The MSP Vaccine Company.
Monfembere® is a registered trademark of Sumitomo Pharma Switzerland GmbH.

Forward-Looking Statements
This press release contains certain forward-looking statements relating to our business, including our plans to develop and commercialize DNA medicines and our expectations regarding our research and development programs, including the anticipated submission of a BLA in the second half of 2024 and the anticipated commercial launch of INO-3107 if regulatory approval is obtained. Actual events or results may differ from the expectations set forth herein due to a number of factors, including the uncertainties inherent in preclinical studies, clinical trials, product development programs and commercialization activities and results, the availability of funding to support continued research and studies to prove the safety and efficacy of electroporation technology as a delivery mechanism or to develop viable DNA medicines, our ability to sustain our pipeline of DNA medicine products, the ability of our collaborators to achieve development and commercialization milestones for the products we license and product sales that will allow us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more effective or cost-effective than any therapies or treatments that we and our collaborators hope to develop, product liability issues, patent issues and whether patents or licenses granted to them will provide us with meaningful protection against others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe the rights of others or resist claims of invalidity and whether we can fund or devote other significant resources that may be necessary to pursue, protect or defend them, the level of company expenses, evaluations of our technology by potential partners or collaborators of the company or other partners, capital market conditions, the impact of government health care proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2019. December 31, 2023our quarterly report on Form 10-Q for the quarter ended March 31, 2024and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured or commercialized, that the results of clinical trials will support the regulatory approvals required to commercialize the products, or that the forward-looking information provided herein will prove to be accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as required by law.

Contacts
Media: Jennie Willson (267) 429-8567 (protected email)
Investors: Thomas Hong (267) 440-4298 (protected email)

SOURCE INOVIO Pharmaceuticals, Inc.